PL376509A1 - Antagoniści IL-15 - Google Patents

Antagoniści IL-15

Info

Publication number
PL376509A1
PL376509A1 PL03376509A PL37650903A PL376509A1 PL 376509 A1 PL376509 A1 PL 376509A1 PL 03376509 A PL03376509 A PL 03376509A PL 37650903 A PL37650903 A PL 37650903A PL 376509 A1 PL376509 A1 PL 376509A1
Authority
PL
Poland
Prior art keywords
antagonists
Prior art date
Application number
PL03376509A
Other languages
English (en)
Inventor
Ingeborg Dreher
Thomas Moll
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL376509A1 publication Critical patent/PL376509A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5443IL-15
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL03376509A 2002-10-14 2003-10-13 Antagoniści IL-15 PL376509A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022869 2002-10-14

Publications (1)

Publication Number Publication Date
PL376509A1 true PL376509A1 (pl) 2005-12-27

Family

ID=32103882

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376509A PL376509A1 (pl) 2002-10-14 2003-10-13 Antagoniści IL-15

Country Status (12)

Country Link
US (1) US20060236411A1 (pl)
EP (1) EP1554307A2 (pl)
JP (1) JP2006518583A (pl)
KR (1) KR20050049545A (pl)
CN (1) CN1703423A (pl)
AU (1) AU2003269659A1 (pl)
BR (1) BR0315327A (pl)
CA (1) CA2502316A1 (pl)
MX (1) MXPA05003887A (pl)
PL (1) PL376509A1 (pl)
RU (1) RU2005114526A (pl)
WO (1) WO2004035622A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN100334112C (zh) * 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CN101831435B (zh) * 2010-05-10 2013-09-11 昆山贝瑞康生物科技有限公司 小鼠il-15亚型蛋白的制备及其应用
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
SG10201605397PA (en) 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2014207173A1 (en) * 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
PL3235830T3 (pl) * 2014-12-19 2020-12-14 Jiangsu Hengrui Medicine Co., Ltd. Kompleks białkowy interleukiny 15 i jego zastosowanie
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP3810171B1 (en) * 2018-06-22 2025-07-09 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof
EP3820571A1 (en) * 2018-07-10 2021-05-19 University of Connecticut Reagents and methods for treating cancer and autoimmune disease
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
JP7807076B2 (ja) * 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン-15(il-15)融合タンパク質およびその使用
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5698765A (en) * 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) * 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) * 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−1遺伝子の機能が欠損したマウス
DE69534265T2 (de) * 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
WO1997041232A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15

Also Published As

Publication number Publication date
AU2003269659A1 (en) 2004-05-04
RU2005114526A (ru) 2005-10-10
US20060236411A1 (en) 2006-10-19
EP1554307A2 (de) 2005-07-20
WO2004035622A2 (de) 2004-04-29
KR20050049545A (ko) 2005-05-25
CN1703423A (zh) 2005-11-30
BR0315327A (pt) 2005-08-16
CA2502316A1 (en) 2004-04-29
MXPA05003887A (es) 2005-10-18
JP2006518583A (ja) 2006-08-17
WO2004035622A3 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
PL376509A1 (pl) Antagoniści IL-15
IL165841A0 (en) Mchir antagonists
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (pl) Nowe pochodne pirydyny i pirymidyny
PL373598A1 (pl) Nowe benzonaftyrydyny
GB0206048D0 (en) Use
IL163652A0 (en) Substituted hydroxyethylamines
PL372804A1 (pl) Wibrator
GB0211257D0 (en) Novel heterocycles
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
IL163939A0 (en) Nk1 antagonists
SI1487778T1 (sl) Substituirani 4-aminocikloheksanoli
IL164975A0 (en) Novel combination
GB0226227D0 (en) Receptors
IL166740A0 (en) Substituted heterocyclylpyrimidines
GB0214784D0 (en) Novel combination
GB0209989D0 (en) Novel heterocycles
AU152494S (en) Level
GB0223399D0 (en) Receptors
PL377325A1 (pl) Podstawione benzodioksepiny
GB0204720D0 (en) Novel use
GB0210682D0 (en) Novel use
GB0229743D0 (en) Novel benzoxazocines
GB0209988D0 (en) Novel Heterocycles
IL147930A0 (en) Vibrator

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)